

Vonoprazan-based triple tx feasible for H. pylori

August 25 2016



(HealthDay)—The potassium-competitive acid blocker vonoprazan-

based triple therapy seems safe and effective compared with conventional proton pump inhibitor (PPI)-based triple therapy as first-line treatment against *Helicobacter pylori*, according to a study published online Aug. 17 in the *Journal of Digestive Diseases*.

Satoki Shichijo, M.D., Ph.D., from the University of Tokyo, and colleagues performed a multicenter study involving 2,715 patients who received first-line *H. pylori* eradication therapy. Vonoprazan-based triple therapy was compared with conventional PPI-based triple therapy.

The researchers found that eradication rates were 87.2 and 72.4 percent for vonoprazan-based and conventional PPI-based therapy, respectively (P

"Vonoprazan-based [triple therapy](#) is feasible; it showed a higher eradication rate than conventional PPIs as a first-line regimen," the authors write.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Vonoprazan-based triple tx feasible for H. pylori (2016, August 25) retrieved 10 April 2024 from <https://medicalxpress.com/news/2016-08-vonoprazan-based-triple-tx-feasible-pylori.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
